{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-027463","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.830278+00:00","generated_at":"2026-06-11T19:20:12.919379+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Indaptus completes first Decoy20 cohort; starts second cohort","bullets":["Three patients completed 28-day safety review; one grade 3 bradycardia (reversible) and two grade 3 AST increases resolved.","Other adverse events (chills, fatigue, vomiting, fever) were grade 1-2 and resolved quickly.","Immune activation observed via transient expression of cytokines/chemokines associated with innate and adaptive pathways.","Second cohort initiated after Safety Review Committee review per protocol."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-027463","json":"https://secwatch.observer/filing/0001493152-23-027463.json","markdown":"https://secwatch.observer/filing/0001493152-23-027463.md","text":"https://secwatch.observer/filing/0001493152-23-027463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223027463/0001493152-23-027463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223027463/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:20:12.919379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}